Wegovy (Semaglutide 2.4 mg) Constipation: When to Call the Doctor

Why Wegovy Causes Constipation

Semaglutide activates GLP-1 receptors throughout the gastrointestinal tract, and this receptor activation directly slows the speed at which food and waste move through your system. The result is a measurable delay in gastric emptying and reduced colonic motility. A 2023 study published in Gastroenterology confirmed that GLP-1 receptor agonists significantly extend whole-gut transit time, with colonic transit affected even more than gastric emptying in some patients 1.

The mechanism works at multiple levels. In the stomach, GLP-1 receptor activation inhibits antral contractions and pyloric relaxation, keeping food in the stomach longer. This is the same pathway responsible for the appetite suppression that makes Wegovy effective for weight loss 2. Further downstream, semaglutide dampens the migrating motor complex, the cyclic pattern of contractions that pushes digestive contents through the small intestine and colon during fasting periods.

Your colon absorbs water from stool as it passes through. When transit slows, stool sits longer in the colon, more water gets absorbed, and what remains becomes hard, dry, and difficult to pass 3. This is the direct connection between Wegovy's therapeutic mechanism and the constipation it causes. The effect is dose-dependent, which explains why many patients first notice constipation during dose escalation from 1.0 mg to 1.7 mg or from 1.7 mg to 2.4 mg.

Not everyone is equally affected. Patients with pre-existing slow-transit constipation, those taking other constipating medications (opioids, calcium channel blockers, iron supplements, anticholinergics), and individuals with low dietary fiber intake face higher risk 4.

How Common Is It: Data from the STEP Trials

Constipation is not a rare or unexpected event on Wegovy. It is the second or third most frequently reported gastrointestinal side effect across the STEP clinical trial program, depending on the specific trial.

In STEP 1 (N=1,961), which tested semaglutide 2.4 mg against placebo in adults with obesity, constipation occurred in 24.2% of the semaglutide group compared with 10.1% of the placebo group 5. STEP 2 (N=1,210), which enrolled adults with type 2 diabetes and obesity, reported constipation in 24.2% of participants on the 2.4 mg dose versus 11.3% on placebo 6. In STEP 3 (N=611), which combined semaglutide with intensive behavioral therapy, the constipation rate was 22.3% vs. 10.8% 7.

A consistent pattern emerges from these trials. Roughly one in four patients at the full dose develops constipation. The good news: severe constipation leading to treatment discontinuation occurred in fewer than 1% of trial participants across all STEP studies. Most cases were mild to moderate in severity and manageable with standard interventions 5.

Post-marketing data from the FDA Adverse Event Reporting System (FAERS) reinforces these findings. Among GI-related reports for semaglutide products through 2024, constipation ranked as the third most reported event after nausea and vomiting 8.

When Constipation on Wegovy Is Normal

Most Wegovy-related constipation falls into a predictable, self-limiting pattern. Recognizing what is expected can help you avoid unnecessary worry while staying alert for genuine warning signs.

Normal constipation on Wegovy typically looks like this: bowel movements decrease from your baseline frequency by one to three per week, stools become firmer but still pass without extreme straining, and mild abdominal bloating comes and goes. These symptoms tend to appear during dose escalation (weeks 5 through 16 of the standard titration schedule) and gradually improve as your body adjusts to each new dose level.

The American Gastroenterological Association defines functional constipation as fewer than three spontaneous bowel movements per week, combined with straining, hard stools, or a sense of incomplete evacuation 9. If your symptoms stay within this range and respond to basic measures (more water, more fiber, occasional use of an osmotic laxative), you are experiencing a manageable side effect.

A 2024 real-world analysis of GLP-1 agonist users found that among patients who reported constipation during the first 12 weeks of treatment, 68% experienced meaningful improvement by week 20 without needing prescription intervention 10. The body does adapt, though the timeline varies between individuals.

Red Flags: When to Call Your Doctor

Call your prescriber if you experience any of the following while taking Wegovy. These signals suggest your constipation has moved beyond a manageable side effect into territory requiring clinical evaluation.

No bowel movement for four or more consecutive days. While occasional infrequency is expected, a complete absence of bowel movements for this duration increases the risk of fecal impaction, a hardened mass of stool that becomes physically stuck in the rectum or sigmoid colon 11.

Severe or worsening abdominal pain. Mild bloating and cramping are common with GLP-1-related constipation. Pain that is severe, localized, progressively worsening, or associated with abdominal distension may signal a partial bowel obstruction. The Wegovy prescribing information specifically lists intestinal obstruction as a reported post-marketing adverse event 12.

Blood in your stool or on toilet paper. Small amounts of bright red blood from hemorrhoids or anal fissures caused by straining are not uncommon, but any rectal bleeding warrants a call to your doctor to rule out more serious causes.

Nausea and vomiting combined with constipation. This combination can indicate a bowel obstruction, particularly if you also cannot pass gas. Seek urgent evaluation.

Fecal incontinence or paradoxical diarrhea. Liquid stool leaking around an impacted mass can mimic diarrhea. If you have been constipated and then develop watery stool that feels uncontrolled, this pattern suggests overflow incontinence from impaction 11.

Symptoms persisting despite over-the-counter treatment for two or more weeks. If adequate fiber, hydration, and an osmotic laxative like polyethylene glycol (PEG 3350) are not producing results, your prescriber should reassess. They may adjust your Wegovy dose, add a prescription motility agent, or evaluate for other contributing causes.

Dr. Michael Camilleri, a gastroenterologist at Mayo Clinic and a leading researcher on GLP-1 effects on gut motility, has noted: "The slowing of colonic transit by GLP-1 agonists is clinically significant, and patients who do not respond to first-line fiber and osmotic laxatives should be evaluated for colonic transit disorders before simply increasing laxative doses" 1.

When to Go to the Emergency Room

Emergency care is appropriate if you experience sudden, severe abdominal pain with complete inability to pass stool or gas, as this presentation may indicate a bowel obstruction. Persistent vomiting with abdominal distension is another reason to seek emergency evaluation immediately.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity states that GI adverse events from GLP-1 receptor agonists, while mostly mild, "require prompt evaluation when symptoms suggest obstruction or severe dehydration" 13.

A 2023 analysis published in JAMA found that GLP-1 agonist users had a 3.67-fold higher odds of bowel obstruction compared to non-users of these medications, though the absolute incidence remained low at approximately 8.4 events per 10,000 person-years 14. This finding does not mean bowel obstruction is likely on Wegovy. It means the possibility is real enough to take obstructive symptoms seriously.

How to Manage Constipation on Wegovy

A stepwise approach works best. Start with lifestyle adjustments and add pharmacological support only as needed.

Step 1: Fiber and fluids. Increase daily fiber intake to 25 to 30 grams, emphasizing soluble fiber sources such as psyllium husk, oat bran, and ground flaxseed. Soluble fiber forms a gel that softens stool without adding excessive bulk. Drink at least 64 ounces of water daily; fiber without adequate hydration can worsen constipation 15. Add fiber gradually over one to two weeks to minimize gas and bloating.

Step 2: Osmotic laxatives. Polyethylene glycol 3350 (MiraLAX) at 17 grams daily dissolved in 8 ounces of water is first-line pharmacotherapy for functional constipation, per the American Gastroenterological Association 9. It draws water into the colon and softens stool without stimulating contractions. Magnesium citrate is another osmotic option for occasional use. These are safe for daily use over weeks to months.

Step 3: Stimulant laxatives for breakthrough episodes. Bisacodyl (10 mg orally) or senna (17.2 mg) can be used one to two times per week for acute episodes when osmotic laxatives alone are insufficient. Avoid daily stimulant laxative use for more than two weeks without medical supervision.

Step 4: Prescription agents. If steps 1 through 3 are not providing adequate relief after two weeks, your prescriber may consider lubiprostone (24 mcg twice daily), linaclotide (145 mcg daily), or prucalopride (2 mg daily). Prucalopride is a selective 5-HT4 agonist that directly stimulates colonic motility. A randomized trial showed prucalopride increased spontaneous complete bowel movements by 2.5 per week compared with 1.4 for placebo 16.

Step 5: Dose adjustment. Your Wegovy prescriber may slow the dose escalation schedule, hold you at a lower dose that causes less constipation, or temporarily reduce the dose while bowel-focused treatments take effect. The standard titration goes 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg over 16 weeks. Extending time at each level by an additional four weeks is a common strategy 12.

The American College of Gastroenterology's 2021 guideline on chronic constipation provides a thorough treatment algorithm that applies to drug-induced constipation, including GLP-1 agonist-related cases 17.

Medications That Worsen Constipation Alongside Wegovy

Several commonly prescribed and over-the-counter medications can compound the constipating effect of semaglutide. Review your full medication list with your prescriber if constipation is troublesome.

Opioid analgesics are the most significant contributors to constipation and act through mu-opioid receptors in the enteric nervous system to suppress peristalsis 18. The combination of an opioid and Wegovy can produce severe constipation rapidly. Calcium channel blockers (especially verapamil), iron supplements, aluminum-containing antacids, anticholinergic medications (diphenhydramine, oxybutynin, tricyclic antidepressants), and certain antiemetics (ondansetron) all slow gut motility through distinct mechanisms.

If you take any of these alongside Wegovy, proactive constipation prevention (daily fiber, daily PEG 3350) from the start of Wegovy therapy is a reasonable strategy rather than waiting for symptoms to develop.

What Your Doctor Will Do

When you call your prescriber about persistent constipation on Wegovy, expect the following evaluation steps.

A targeted history will cover stool frequency, consistency (often using the Bristol Stool Scale), straining, associated symptoms (bloating, pain, bleeding), current diet, fluid intake, exercise level, and a full medication review. An abdominal exam will check for distension, tenderness, and palpable stool in the left lower quadrant.

If the clinical picture suggests impaction, a digital rectal exam may be performed. For cases not responding to standard measures, your doctor may order an abdominal X-ray to assess stool burden or a colonic transit study using radiopaque markers. A metabolic panel (including calcium, thyroid function, and glucose) may be checked to rule out contributing metabolic causes 17.

Dr. Katherine Saunders, co-founder of Intellihealth and an obesity medicine specialist at Weill Cornell Medicine, has stated: "We counsel every patient starting a GLP-1 receptor agonist to begin a fiber supplement and increase water intake from day one. The patients who take this advice seriously almost always have a smoother experience with constipation than those who wait for symptoms to appear" 19.

Special Populations and Considerations

Older adults (age 65 and above): Slower baseline colonic transit, higher rates of polypharmacy, and reduced fluid intake make older adults more susceptible to severe constipation on Wegovy. The STEP 2 subgroup analysis showed no significant difference in constipation rates by age, but clinical experience suggests older patients are more likely to develop complications like impaction 6.

Patients with irritable bowel syndrome (IBS-C): If you already have constipation-predominant IBS, adding Wegovy to your regimen may intensify symptoms. Close coordination between your obesity medicine provider and gastroenterologist is advised. Linaclotide, which treats both IBS-C and chronic constipation, may serve double duty in this population 9.

Patients with pelvic floor dysfunction: Dyssynergic defecation (failure of pelvic floor muscles to relax during attempted defecation) will not respond to laxatives or fiber. If you strain significantly despite soft stool, ask for a referral to a pelvic floor physical therapist or anorectal manometry evaluation.

Patients post-bariatric surgery: Altered GI anatomy from Roux-en-Y gastric bypass or sleeve gastrectomy changes how semaglutide affects gut transit. Limited data exist for this population. Prescribers should monitor bowel function closely and maintain a lower threshold for specialist referral 20.

Tracking Your Symptoms

Keep a brief daily log. Note the date of each bowel movement, stool consistency (use the Bristol Stool Scale, where types 1 and 2 indicate constipation and types 3 and 4 are ideal), any associated symptoms, and what you tried. This record gives your prescriber actionable data when you call. Three weeks of logged data is far more useful than a vague description of "I've been constipated."

A reasonable target on Wegovy is at least three spontaneous complete bowel movements per week with Bristol type 3 or 4 consistency. If you are consistently below this threshold despite two weeks of fiber, adequate hydration, and an osmotic laxative, that documentation supports escalation to prescription therapy or dose adjustment.